Immix Biopharma Statistics
Total Valuation
Immix Biopharma has a market cap or net worth of $51.01 million. The enterprise value is $34.40 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immix Biopharma has 27.72 million shares outstanding. The number of shares has increased by 63.11% in one year.
| Current Share Class | 27.72M |
| Shares Outstanding | 27.72M |
| Shares Change (YoY) | +63.11% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 20.99% |
| Owned by Institutions (%) | 15.59% |
| Float | 17.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.64 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.33 |
| Quick Ratio | 2.26 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -147.33% and return on invested capital (ROIC) is -92.84%.
| Return on Equity (ROE) | -147.33% |
| Return on Assets (ROA) | -66.11% |
| Return on Invested Capital (ROIC) | -92.84% |
| Return on Capital Employed (ROCE) | -159.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.03M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immix Biopharma has paid $41,037 in taxes.
| Income Tax | 41,037 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.62% in the last 52 weeks. The beta is 0.29, so Immix Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -13.62% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 1.87 |
| Relative Strength Index (RSI) | 61.09 |
| Average Volume (20 Days) | 43,019 |
Short Selling Information
The latest short interest is 346,837, so 1.25% of the outstanding shares have been sold short.
| Short Interest | 346,837 |
| Short Previous Month | 367,356 |
| Short % of Shares Out | 1.25% |
| Short % of Float | 1.93% |
| Short Ratio (days to cover) | 6.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.67M |
| Pretax Income | -18.18M |
| Net Income | -21.61M |
| EBITDA | -22.64M |
| EBIT | -22.67M |
| Earnings Per Share (EPS) | -$0.76 |
Full Income StatementBalance Sheet
The company has $17.68 million in cash and $1.07 million in debt, giving a net cash position of $16.61 million or $0.60 per share.
| Cash & Cash Equivalents | 17.68M |
| Total Debt | 1.07M |
| Net Cash | 16.61M |
| Net Cash Per Share | $0.60 |
| Equity (Book Value) | 13.25M |
| Book Value Per Share | 0.48 |
| Working Capital | 11.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.60 million and capital expenditures -$1.18 million, giving a free cash flow of -$15.77 million.
| Operating Cash Flow | -14.60M |
| Capital Expenditures | -1.18M |
| Free Cash Flow | -15.77M |
| FCF Per Share | -$0.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |